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Autoinflammatory disorders
Polymyalgia rheumatica (PMR) is an 
elderly onset syndrome characterised by 
aching and stiffness in the shoulders and the 
pelvic girdle associated to increased levels 
of acute phase reactants and rapid response 
to glucocorticoids.1 Although the cause of 
PMR remains unknown, most of the evidence 
suggest a multifactorial aetiology inducing an 
immunomediated pathogenesis.1 2
According to the ‘immunological 
continuum model’ proposed by McGonagle 
in 2006, all immune-mediated diseases can 
be conceptualised as predominantly auto-
inflammatory, predominantly autoimmune 
or mixed, on the basis of the relative contri-
butions of innate and adaptive immune 
responses.3 Autoinflammatory diseases 
(AIDs) are characterised by tissue inflam-
mation mainly due to aberrant activation of 
innate immune system without autoantibodies 
production and autoreactive T lymphocyte 
activation. In contrast, autoimmune diseases 
(ADs) are typically depicted by an abnormal 
activation of the adaptive immune system.4 
However, the emerging understanding of the 
close linkage between innate and adaptive 
immunity led to consider the rare monogenic 
AIDs and ADs as the two opposite ends into 
a continuum of immune-mediated disor-
ders, where middle entities are recognised 
(figure 1).3
In the view of this background, we tried to 
envisage the most suitable place for PMR into 
the spectrum of the autoinflammatory/auto-
immune disorders by reviewing and inter-
preting current evidence.
Clear indication for a prevalent autoinflam-
matory background of PMR is related to the 
disease onset and course. Actually, starting 
of symptoms is generally over a few days or 
overnight in PMR,1 as well as in inflammatory 
periodic-recurring occurrence of AIDs,5 but 
in contrast to classic polygenic ADs where 
a subacute onset is frequently recorded 
(figure 2A).6 Further, after low-dose gluco-
corticoid therapy initiation, patients with 
PMR experience a rapid improvement of 
symptoms, generally within 24–72 hours, and 
more than 40% of them achieve complete 
response within 3 weeks.1 Similarly, in rare 
monogenic AIDs, a rapid remission of symp-
toms and significant reduction in frequency 
of inflammatory attacks is rapidly achieved 
with specific treatment, such as colchicine in 
familial Mediterranean fever (FMF) and inter-
leukin-1β (IL-1β) blockade in cryopyrin-as-
sociated periodic syndrome.7 Conversely, a 
chronic or relapsing-remitting course, with a 
minimal residual disease activity and progres-
sive damage accrual, is frequently recorded in 
ADs (figure 2B).8
Age of onset and gender distribution are 
inconclusive in discriminating the prevalent 
autoinflammatory or autoimmune nature 
of PMR (figure 2C). Indeed, both in ADs 
and AIDs elderly onset is rare, and the main 
determinant of the onset age is the mono-
genic (childhood) or polygenic (adulthood) 
nature of the disease.4 9 Further, the prefer-
ential involvement of woman in PMR (female 
to male ratio=2:1) seems related to a different 
and currently unknown mechanism than the 
arise in oestrogen production reported as 
one of the main determinants of the female 
prevalence in typical ADs, such as systemic 
lupus erythematosus (SLE) (female to male 
ratio=9:1).1 9
Laboratory findings lean towards a predom-
inant role of innate immune response in 
PMR. Indeed, a remarkable increase of 
inflammatory markers is one of the most 
consistent features in patients with both PMR 
and AIDs, so that it is included into the diag-
nostic criteria and monitoring parameters for 
both conditions.1 7 Increase of acute phase 
reactants can also occur in ADs, but with 
lower frequency and diagnostic accuracy 
(figure 2D).4 Further, autoantibodies carrying 
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a significant pathogenic and/or diagnostic role have not 
been identified in PMR, as well as in AIDs,4 whereas they 
are frequently associated to prototypical ADs (eg, anti-
double-stranded DNA in SLE, anti-citrullinated peptide 
in rheumatoid arthritis (RA)) (figure 2E).4 10 Noteworthy, 
lack of pathogenetic autoantibodies is typically recorded 
in other immune-mediated diseases, such as the major 
histocompatibility complex class I (MHC-I)-pathies 
(eg, ankylosing spondylitis, psoriatic arthritis) that are 
reported as prototypical mixed autoinflammatory/auto-
immune disorders in the immunological continuum.3
Similar to AIDs and in contrast to what is reported 
for typical ADs, not significant overlap has been identi-
fied between PMR and other immunological disorders, 
excepting for giant cell arteritis (GCA).11 However, it is 
still unclear whether GCA represents a separate condi-
tion from PMR or a potential expression of the same 
disease (figure 2).3 12 Further, a mixed contribution of 
innate and adaptive immunity, supported by the bringing 
function of Th17 cells, has been recognised in the GCA.1
Despite the widely incomplete knowledge on pathogen-
esis of PMR, some suggestions for a predominant autoin-
flammatory nature of the disease arise from the genetic 
background and cytokine profile. Indeed, a clear associ-
ation between human leukocyte antigen (HLA) class II 
alleles (especially HLA-DRB1*0401) and isolated PMR 
has not been definitely demonstrated due to conflicting 
data from different populations.1 On the other hand, 
HLA class II alleles have been found to associate with 
GCA susceptibility and GCA with PMR symptoms, as 
well as in most of ADs (figure 2G).13–15 Polymorphisms 
of additional genes involved in initiating and regulating 
inflammatory response, such as intercellular adhesion 
molecule-1, tumour necrosis factor (TNF), interleukin 6 
(IL-6) and interleukin 1 (IL-1) receptor antagonist 
(IL-1RN) have also been identified as possible suscepti-
bility factors for PMR.16 Interestingly, Alvarez-Rodriguez 
reported that the IL-1RN*2 polymorphism in a homo-
zygous state associated to higher susceptibility to PMR 
when compared with healthy controls and GCA, as well as 
to elderly onset RA (EORA) when compared with young-
onset RA.15
Regarding the cytokine profile, evidence of a IL-6 
central pathophysiological role in PMR has been 
provided. Remarkably, among rheumatic diseases, the 
highest serum levels of IL-6 were found in patients 
affected by PMR and GCA17 as well as in EORA.18 The 
latter presents some not canonical features compared with 
traditional ADs (eg, lower prevalence of autoantibodies, 
reduced prevalence in females, less straight association 
with HLA-II) and might be part of an autoinflammatory–
autoimmune mixed subtype of RA.19 Further, in contrast 
to several ADs, increased levels of serum interferon-γ 
(IFN-γ) were not found in PMR. Moreover, IFN-γ was 
observed in the temporal artery biopsy (TAB) specimens 
of GCA patients, while it was not seen in TAB of patients 
with isolated PMR, suggesting a key role of this cytokine 
in the progression to overt arteritis.20 Finally, increased 
level of circulating type I IFN has not been reported 
neither on PMR and GCA21 and no data are currently 
available on type I IFN signature, which is considered an 
hallmark of several ADs (figure 2H).
Further pathobiological findings supporting the key 
role of innate immunity in PMR pathogenesis are repre-
sented by the increased expression of toll-like receptor 
(TLR)-7 and TLR-9 in peripheral blood monocytic cells 
and the emerging involvement of Th17 cells.22
To date, glucocorticoids remain the cornerstone of 
treatment for PMR, whereas poor evidence is available 
on the effectiveness of traditional immunosuppres-
sants. Methotrexate (MTX) is the most used glucocor-
ticoid-sparing agent in PMR, although randomised 
controlled trials data on relapse rate and cumulative 
glucocorticoid dose reduction are conflicting.23 Poten-
tial benefit of MTX may be related to antinflammatory 
effects, resulting from reduced monocytic cell activation, 
decreased IL-1 and IL-6 secretion, as well as from inhi-
bition of cyclo-oxygenases synthesis, neutrophil chemo-
taxis and adhesion molecules expression.24 Traditional 
immunosuppressants are generally not used in AIDs 
because of the poor effectiveness in the management of 
attacks and prevention of relapse.7 25 Conversely, tradi-
tional immunosuppressants are the first-line treatment 
in most of ADs, while glucocorticoids can be associated 
Figure 1  Simplified classification of immune-mediated disease by McGonagle and McDermott.3
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Figure 2  Summary of our interpretation of scientific data on polymyalgia rheumatica, in the view of its classification in the 
spectrum of immune-mediated diseases.
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as adjuvant therapy, especially in the induction phase of 
the treatment (figure 2I).26
Experience from patients with PMR symptoms in GCA 
and data from an open-label uncontrolled study on 20 
subjects with isolated PMR suggest anti-IL-6R therapy as 
an effective option in reducing Disease Activity Score and 
reducing cumulative exposition to glucocorticoids (gluco-
corticoid-sparing effect at 24 weeks is 70.2%).27 Anti-
IL-6R also showed promising results in several AIDs, such 
as systemic juvenile idiopathic arthritis, Behçet disease, 
FMF and TNF receptor-associated periodic syndrome.28 
Most of current data on anti-TNFα treatment suggest it is 
ineffective, expensive and potentially harmful in patients 
with PMR.1 Positive results in terms of effectiveness were 
detected for connective tissue diseases and other ADs, 
but its use is limited by the observation of several cases 
of anti-TNFα-induced autoimmune disorders.29 Inter-
estingly, PMR is not reported among the immune-me-
diated paradoxical effect of anti-TNFα (figure 2J). Data 
on anti-IL-1β are limited to a single blind study, where 
canakinumab was administered to three patients with 
new-onset PMR, with not conclusive results in terms of 
effectiveness.30 Therefore, further data from large trial 
on anti-IL-1β in PMR would be warranted.
In summary, despite the incomplete knowledge of 
PMR pathophysiology and the lack of validate discrimina-
tive criteria for polygenic AIDs, current evidence suggests 
that PMR does not easily fit into any of the two pure ends 
in the spectrum of the immune-mediated disorders, but 
a greater affinity for AIDs seems to emerge.
In our opinion, this interpretation of the available scien-
tific data might represent an insight with a significant 
practical implication. Indeed, among the unmet needs in 
PMR, there is the availability of effective and safety ther-
apeutic options for patients not adequately responsive or 
requiring longer exposition to glucocorticoids or with 
an unfavourable risk profile of steroid-related adverse 
effects. In this view, the recognition of predominantly 
autoinflammatory nature of PMR should address future 
research aimed to develop targeted therapies. 
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